-
Views
-
Cite
Cite
B. Miernik, V. Schmidt, K. Technau‐Hafsi, J. S. Kern, F. Meiss, Alitretinoin in the treatment of palmoplantar mycosis fungoides: a new and promising therapeutic approach, Clinical and Experimental Dermatology, Volume 40, Issue 4, 1 June 2015, Pages 445–447, https://doi.org/10.1111/ced.12516
Close - Share Icon Share
Extract
Conflict of interest: the authors declare that they have no conflicts of interest.
BM and VS contributed equally to this study, and should be considered joint first authors.
Mycosis fungoides (MF) is a low‐grade lymphoproliferative disorder. MF primarily restricted to the palmoplantar region is a rare subtype of this group of cutaneous T‐cell lymphomas (CTCLs).1 If standard therapies fail, treatment becomes challenging. We took advantage of the antiproliferative and immune‐modulating effects of alitretinoin (9‐cis‐retinoic‐acid), a drug approved for the treatment of chronic hand eczema, and we report its successful use in treating palmoplantar MF.2,3,4
A 60‐year‐old woman presented with a 5‐month history of hyperkeratotic palmoplantar lesions. Repeated previous skin biopsies were suggestive for eczema or eczematous psoriasis. Several therapeutic strategies including topical corticosteroids, keratolytic ointments and cream psoralen plus ultraviolet A (PUVA) therapy had been tried without effect.
On physical examination, sharply defined scaling erythema, with hyperkeratosis and rhagades, was observed in the palmoplantar region (Fig. 1). Apart from a few nummular erythematous plaques on the patient's lower legs and abdomen, no further involvement of MF was present.
